About: Evaluation of antiviral - passive - active immunization (“sandwich”) therapeutic strategy for functional cure of chronic hepatitis B in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of antiviral - passive - active immunization (“sandwich”) therapeutic strategy for functional cure of chronic hepatitis B in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Evaluation of antiviral - passive - active immunization (“sandwich”) therapeutic strategy for functional cure of chronic hepatitis B in mice
Creator	Li, Jianhua Ying, Tianlei Wu, Yanling Wang, Bin Wang, Chunyu Yuan, Zhenghong Liang, Mifang Li, Xiaofang Shi, Bisheng Wen, Yumei Yang, Zhenlin Yu, Fan
topic	covid:b6ea35cdd357c55dddb3b9732487e664a26cc502#this
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Chronic Hepatitis B (CHB) remains a major problem for global public health. Viral persistence and immune defects are the two major reasons for CHB, and it was hypothesized that based on a transient clearance of serum viral DNA and HBsAg “window stage”, active immunization against hepatitis B virus (HBV) might initiate effective host immune responses versus HBV to achieve functional cure of CHB. METHODS: Two experimental mouse models that mice hydrodynamic injected HBV DNA or infected with recombinant AAV/HBV were used. The “sandwich” therapeutic effect by using a potent human anti-HBsAg neutralizing monoclonal antibody (G12) in combination with antiviral drug tenofovir disoproxil fumarate (TDF), followed by active immunization with HBsAg-HBsAb (mYIC) was evaluated. FINDINGS: A single G12 injection rapidly cleared serum HBsAg in HDI-HBV carrier mice, with a synergistic effect in decreasing viral DNA load when TDF was given orally. When both serum viral DNA and HBsAg load became low or undetectable, mYIC was administered. A more effective clearance of viral DNA and HBsAg was observed and serum HBsAb was developed only in these “sandwich”-treated mice. Efficient intrahepatic anti-HBV immune responses were also observed in these mice, including the formation of aggregates of myeloid cells with CD8(+)T cells and increased TNF-α, granzyme B production. INTERPRETATION: The “sandwich” combination therapy not only efficiently decreased HBsAg and HBV DNA levels but also induced effective cellular and humoral immunity, which may result in functional cure of CHB.
has issue date	2019-11-01(xsd:dateTime)
bibo:doi	10.1016/j.ebiom.2019.10.043
bibo:pmid	31680000
has license	cc-by-nc-nd
sha1sum (hex)	b6ea35cdd357c55dddb3b9732487e664a26cc502
schema:url	https://doi.org/10.1016/j.ebiom.2019.10.043
resource representing a document's title	Evaluation of antiviral - passive - active immunization (“sandwich”) therapeutic strategy for functional cure of chronic hepatitis B in mice
has PubMed Central identifier	PMC6945269
has PubMed identifier	31680000
schema:publication	EBioMedicine
resource representing a document's body	covid:b6ea35cdd357c55dddb3b9732487e664a26cc502#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/b6ea35cdd357c55dddb3b9732487e664a26cc502
is schema:about of	named entity 'CHRONIC HEPATITIS B' named entity 'USING' named entity 'METHODS' named entity 'ADMINISTERED' named entity 'HBV DNA' named entity 'HBSAB' named entity 'LOW' named entity 'MYELOID CELLS' named entity 'SINGLE' named entity 'DECREASING' named entity 'EFFICIENT' named entity 'VIRAL DNA' named entity 'ANTIVIRAL DRUG' named entity 'BASED' named entity 'FORMATION' named entity 'EFFECT' named entity 'CD8' named entity 'TDF' named entity 'CLEARANCE' named entity 'FOLLOWED BY' named entity 'INFECTED' named entity 'HDI' named entity 'INITIATE' named entity 'TRANSIENT' named entity 'USED' named entity 'AAV' named entity 'ANTIVIRAL' named entity 'TENOFOVIR DISOPROXIL FUMARATE' named entity 'LOAD' named entity 'PROBLEM' named entity 'INCLUDING' named entity 'ACTIVE IMMUNIZATION' named entity 'PASSIVE' named entity 'FUNCTIONAL' named entity 'BACKGROUND' named entity 'SYNERGISTIC' named entity 'MAJOR' named entity 'ORALLY' named entity 'RAPIDLY' named entity 'COMBINATION' named entity 'SERUM' named entity 'FUNCTIONAL' named entity 'PUBLIC HEALTH' named entity 'CURE' named entity 'THERAPEUTIC' named entity 'EVALUATION' named entity 'G12' named entity 'VIRAL PERSISTENCE' named entity 'CHRONIC HEPATITIS B' named entity 'T CELLS' named entity 'HYDRODYNAMIC' named entity 'HBV CARRIER' named entity 'MICE' named entity 'RECOMBINANT' named entity 'MICE' named entity 'STRATEGY' named entity 'INCREASED' named entity 'MOUSE MODELS' named entity 'REASONS' named entity 'THESE' named entity 'GLOBAL' named entity 'HBV' named entity 'HUMAN' named entity 'IMMUNE RESPONSES' named entity 'EFFECTIVE' named entity 'GIVEN' named entity 'EVALUATED' named entity 'UNDETECTABLE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software